HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Beijing Tongrentang Co A / Equity Bottom-Up

<ul>
<li>2018 was a watershed for Tongrentang. After the incident of using expired honey was exposed and the corruption scandal afterwards, Tongrentang's performance declined significantly and didn’t recover until 2021.</li>
<li>Angong Niuhuang Pill is the major performance driver and also Tongrentang’s core product. Due to the economic downturn, the price increase of Angong Niuhuang Pills could lead to inventory overstocking.</li>
<li>The high growth in 2021 may not be sustained. We lowered our forecast for 2022. Without core competitiveness and high moat, we are conservative about Tongrentang’s long-term outlook.</li>
</ul>


2018 was a watershed for Tongrentang. After the incident of using expired honey was exposed and the corruption scandal afterwards, Tongrentang's performance declined significantly and didn’t recover until 2021.
Angong Niuhuang Pill is the major performance driver and also Tongrentang’s core product. Due to the economic downturn, the price increase of Angong Niuhuang Pills could lead to inventory overstocking.
The high growth in 2021 may not be sustained. We lowered our forecast for 2022. Without core competitiveness and high moat, we are conservative about Tongrentang’s long-term outlook.


Beijing Tongrentang (600085.CH)- Neither Brand Nor Angong Niuhuang Pills Can Secure Future Prospects

<ul>
<li>After a downturn in 2019,Consun has turned things around and achieved amazing results in 2021. Its core business was not affected by VBP. Consun will continue to make further progress.</li>
<li>Consun is undervalued if compared with industry average, the peers and considering its large cash balance. Share prices have decent upside potential, driven by fundamentals, promising outlook and favorable policies.</li>
<li>Wanbangde’s intention to acquire Consun’s shares at high price would also be a catalyst. We recommended investors to follow Consun closely, which has certain investment value based on our analysis.</li>
</ul>


After a downturn in 2019,Consun has turned things around and achieved amazing results in 2021. Its core business was not affected by VBP. Consun will continue to make further progress.
Consun is undervalued if compared with industry average, the peers and considering its large cash balance. Share prices have decent upside potential, driven by fundamentals, promising outlook and favorable policies.
Wanbangde’s intention to acquire Consun’s shares at high price would also be a catalyst. We recommended investors to follow Consun closely, which has certain investment value based on our analysis.


Consun Pharmaceutical (1681HK)- High-Priced Acquisition & Good Performance Show Big Upside Potential

Smartkarma Research Team, Smartkarma

Smartkarma Research

Smartkarma Research Team

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Kato Hong Kong Holdings / Equity Bottom-Up

<p>For our next Webinar, we are happy to welcome Insight Provider <a href="https://www.smartkarma.com/profiles/steven-chen" target="_blank" data-smartkarma-citation="accounts:10934" rel="noopener">Steven Chen</a> , who will break down his quality-focused, business-perspective investing strategy and then dig deeper into some under-appreciated multi-bag picks that his strategy brings forth in China/Hong Kong as well as across Asia-Pacific.</p>
<div>
<div>
<h3>The webinar will be hosted on Wednesday, 7 July 2021, 17:00 SGT/HKT.</h3>
</div>
</div>
<div>
<div>
<div class="content-highlight">
<h2><a href="https://share.hsforms.com/1H9pFZOB-RF2J00kbvMmxcw2c5gj?zoom_webinar_id=87808685654" target="_blank" rel="noopener">Register for the Webinar here</a></h2>
</div>
</div>
<p>Steven Chen is a quality-focused, business-perspective investor with bottom-up opportunistic approaches, an ex-hedge fund analyst on Wall Street, a serial entrepreneur, a strategic advisor, a computer scientist, a free-market capitalist, and a global citizen. He is the founder of Urbem Capital.</p>
</div>

For our next Webinar, we are happy to welcome Insight Provider Steven Chen , who will break down his quality-focused, business-perspective investing strategy and then dig deeper into some under-appreciated multi-bag picks that his strategy brings forth in China/Hong Kong as well as across Asia-Pacific.


The webinar will be hosted on Wednesday, 7 July 2021, 17:00 SGT/HKT.





Register for the Webinar here


Steven Chen is a quality-focused, business-perspective investor with bottom-up opportunistic approaches, an ex-hedge fund analyst on Wall Street, a serial entrepreneur, a strategic advisor, a computer scientist, a free-market capitalist, and a global citizen. He is the founder of Urbem Capital.


Smartkarma Webinar | Top Picks in China / Hong Kong

Quality-first, Business-perspective Strategy, Urbem (HK) Limited

Steven Chen

Quality-first, Business-perspective Strategy

Thematic (Sector/Industry)

<ul>
<li>Plover Bay - a solid year of healthy growth; management looks to 5G as the main engine for the industry;</li>
<li>Beijing Tong Ren Tang Chinese Medicine - turnaround progress delayed by the pandemic, but Mainland market a bright spot;</li>
<li>Bamboos Healthcare - almost no growth during the period, but management confident about the longer term; too early to judge its capital allocation.</li>
</ul>


Plover Bay - a solid year of healthy growth; management looks to 5G as the main engine for the industry;
Beijing Tong Ren Tang Chinese Medicine - turnaround progress delayed by the pandemic, but Mainland market a bright spot;
Bamboos Healthcare - almost no growth during the period, but management confident about the longer term; too early to judge its capital allocation.


Our Takeaways From Recent Results: Plover Bay, BTRTCM, Bamboos Healthcare

Beijing Tong Ren Tang Chinese Medicine / Equity Bottom-Up

<ul>
<li>We tend to avoid turnarounds as they seldom turn;</li>
<li>But Beijing Tong Ren Tang Chinese Medicine can be a rare case in our opinion;</li>
<li>We see the company as being a wide-moat compounding machine, highly hopeful of delivering superior returns on capital when its business condition normalizes (sooner or later);</li>
<li>Simultaneously, the valuation of the share makes sense for alpha-seeking investors with a double-digit hurdle rate.</li>
</ul>


We tend to avoid turnarounds as they seldom turn;
But Beijing Tong Ren Tang Chinese Medicine can be a rare case in our opinion;
We see the company as being a wide-moat compounding machine, highly hopeful of delivering superior returns on capital when its business condition normalizes (sooner or later);
Simultaneously, the valuation of the share makes sense for alpha-seeking investors with a double-digit hurdle rate.


Beijing Tong Ren Tang Chinese Medicine: A Turnaround Worth A Look

Hong Kong

Beijing Tong Ren Tang Chinese Medicine Co. Ltd. is a Chinese medicine manufacturer. The Company mainly develops and produces health products, including patent medicines and health-care products.

Beijing Tong Ren Tang Chinese Medicine (3613 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Beijing Tong Ren Tang Chinese Medicine (3613 HK)

Beijing Tongrentang (600085.CH)- Neither Brand Nor Angong Niuhuang Pills Can Secure Future Prospects

Angong Niuhuang Pill is the major performance driver. Due to economic downturn, its price hike will lead to inventory overstocking. Without high...

Xinyao (Criss) Wang

Consun Pharmaceutical (1681HK)- High-Priced Acquisition & Good Performance Show Big Upside Potential

Consun achieved amazing 2021 results and is undervalued. Wanbangde’s intention to acquire Consun at high price is a catalyst. Shares have big...

Xinyao (Criss) Wang

Smartkarma Webinar | Top Picks in China / Hong Kong

On 7 July, 5pm SGT, join us and Steven Chen, who will break down his quality-focused, business-perspective investing strategy and then dig deeper...

Smartkarma Research

Our Takeaways From Recent Results: Plover Bay, BTRTCM, Bamboos Healthcare

Three HK-listed companies from our Investable Universe reported results recently. Let's take a deep dive into each of them.

Steven Chen

Beijing Tong Ren Tang Chinese Medicine: A Turnaround Worth A Look

Beijing Tong Ren Tang Chinese Medicine can be a rare turnaround case in our opinion, thanks to its wide moat and compounding capability.

Steven Chen

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)